Adenoviral E1a expression levels affect virus-selective replication in human cancer cells

Cancer Biology and Therapy

Volumn 4, Issue 11, 2005, Pages 1255-1262

  Zheng, Xinyu ^a   Rao, Xiao Mei ^a   Snodgrass, Christina ^a   Wang, Min ^a   Dong, Yanbin ^a   McMasters, Kelly M ^a   Zhou, H Sam ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Adenovirus; E1a; Oncolysis; Promoter; Viral replication

Indexed keywords

E1A PROTEIN; E1B PROTEIN; ONCOLYTIC VIRUS;

ADENOVIRUS; ARTICLE; CANCER CELL; CELL TYPE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; WILD TYPE;

EID: 33646423529     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.11.2137     Document Type: Article

References (29)

1. Shenk T. Adenoviridae: The viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott Williams and Wilkins, 2001:2265-300.
2. Bagchi S, Raychaudhuri P, Nevins JR. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: A novel mechanism for E1A trans-activation. Cell 1990; 62:659-69.
3. Bandara LR, La Thangue NB. Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature 1991; 351:494-7.
4. Nevins JR, Leone G, DeGregori J, Jakoi L. Role of the Rb/E2F pathway in cell growth control. J Cell Physiol 1997; 173:233-6.
5. O'Connor RJ, Hearing P. The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection. J Virol 2000; 74:5819-24.
6. Hayflick L, et al. Preparation of poliovirus caccines in a human fetal diploid cell strain. Am J Hyg 1962; 75:240-50.
7. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91:8802-6.
8. Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC, Brenner MK, McMasters KM, Zhou HS. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther 2004; 11:585-93.
9. Graham FL. Manipulation of adenovirus vectors. In: Murray EJ, ed. Methods in Molecular Biology. Clifton, NJ: The Humana Press Inc., 1991:109-28.
10. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70:7030-8.
11. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274:373-6.
12. Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60:1193-6.
13. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6:611-23.
14. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, Phipps S, Chiang YL. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10:1721-33.
15. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106:763-71.
16. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther 2002; 9:270-81.
17. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62:4663-70.
18. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57:2559-63.
19. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59:4200-3.
20. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14:933-46.
21. Hitt MM, Graham FL. Adenovirus E1A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication. Virology 1990; 179:667-78.
22. Osborne TF, Berk AJ. Far upstream initiation sites for adenovirus early region 1A transcription are utilized after the onset of viral DNA replication. J Virol 1983; 45:594-9.
23. Hearing P, Shenk T. The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element. Cell 1983; 33:695-703.
24. Berk AJ. Adnovirus promoters and E1A transactivation. Ann Rev Genet 1986; 20:45-79.
25. Hatfield L, Hearing P. Redundant elements in the adenovirus type 5 inverted terminal repeat promote bidirectional transcription in vitro and are important for virus growth in vivo. Virology 1991; 184:265-76.
26. McCart J, Wang Z, Xu H, Hu Y, Park B, Alexander H, Bartlett D. Development of a melanoma-specific adenovirus. Mol Ther 2002; 6:471.
27. Hearing P, Shenk T. The adenovirus type 5 E1a enhancer contains tow functionally distinct domains: One is specific for E1a and the other modulates all early units in cis. Cell 1986; 45:229-36.
28. Bruder JT, Hearing P. Cooperative binding of EF-1A to the E1A enhancer region mediates synergistic effects on E1A transcription during adenovirus infection. J Virol 1991; 65:5084-7.
29. Grable M, Hearing P. cis and trans requirements for the selective packaging of adenovirus type 5 DNA. J Virol 1992; 66:723-31.